insights_auto
Why is 2X10 up 3.82%?
Dive Deeperchevron_right
2X10:FRA
Abivax SA
€81.50
arrow_upward
+3.82%(+3.00) 1D
Oct 20, 8:15:31 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 2X10...
Open
€78.00
High
€81.50
Low
€78.00
Mkt. cap
6.95B
Avg. vol.
3.00
Volume
0.00
52-wk high
€133.00
52-wk low
€63.50
No. of employees
98
Open
€78.00
High
€81.50
Low
€78.00
Mkt. cap
6.95B
Avg. vol.
3.00
Volume
0.00
52-wk high
€133.00
52-wk low
€63.50
No. of employees
98
News stories
From web sources and news partners
ChartMill
·
1 hour ago
Most Active S&P 500 Stocks in Today's Session
FXEmpire
·
34 minutes ago
Dow Jones Price Forecast: Bulls Eye 57,000 as October 6 Low Remains Key
Insider Monkey
·
2 hours ago
Ciena (CIEN): Is the AI-Optical Boom Enough to Carry It Into the S&P 500?
Yahoo Finance
·
2 hours ago
United Therapeutics (UTHR): Can the Profit-Machine Biotech Finally Crack the S&P 500?
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees98
FoundedDec 4, 2013
Headquarters-
SectorBiotechnology
Websiteabivax.com